CMS and the Medicare private drug plans are using Medicare enrollment to teach seniors -- and their adult advisors -- about the cost savings from therapeutic interchange. Training patients to look for cost savings and to discuss costs with doctors is clearly a secondary objective of the Medicare enrollment process. The Medicare plan finder website and private plan sites carry frequent messages to alert beneficiaries cost savings. Pfizer responds with consumer-based pricing for Lipitor.
Cole Werble
School started Nov. 15 for an accelerated course in pharmaceutical pricing and product switching.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
For the Trump Administration, the blockbuster GLP-1 drugs for obesity have become a poster child for the disparity between US and foreign prices.
Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.
Enrollment in the new Medicare Prescription Payment Plan was lower than expected in the first year and well below CMS expectations, and invoicing data indicates members are slow to pay.
The new FTC chair addressed concerns that staffing cuts will undermine the commission’s commitment to pharmacy benefit manager oversight.
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.
